JAZZ Jazz Pharmaceuticals plc
Healthcare$237.41-1.01%ClosedMarket Cap: $14.90B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.28
P/S
3.39
EV/EBITDA
47.09
DCF Value
$483.39
FCF Yield
8.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.1%
Operating Margin
11.1%
Net Margin
0.7%
ROE
0.7%
ROA
0.2%
ROIC
-0.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.07B | 71.3% | $213.8M | $293.1M | $— | — |
| Q4 null | $1.20B | 97.9% | $909.2M | $203.5M | $— | — |
| FY null | $4.27B | 88.2% | $224.4M | $-356.1M | $— | — |
| Q3 null | $1.13B | 77.1% | $57.5M | $251.4M | $— | — |
| Q2 null | $1.05B | 88.9% | $-686.4M | $-718.5M | $— | — |
| Q1 null | $897.8M | 88.3% | $-55.9M | $-92.5M | $— | — |
| Q4 null | $1.09B | 88.2% | $190.8M | $191.1M | $— | — |
| FY null | $4.07B | 89.0% | $716.6M | $560.1M | $— | — |
| Q3 null | $1.05B | 89.4% | $260.2M | $215.1M | $— | — |
| Q2 null | $1.02B | 89.3% | $199.4M | $168.6M | $— | — |
| Q1 null | $902.0M | 89.4% | $66.2M | $-14.6M | $— | — |
| Q4 2023 | $1.01B | 89.4% | $122.5M | $94.2M | $1.42 | — |